Go Deep
ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -6,705 | -1.9 | 32.19 | 13.71 | 385.70 |
| Oct 2026 | -6,182 | -1.8 | 31.24 | 13.71 | 373.14 |
| Oct 2026 | -6,792 | -1.9 | 32.35 | 13.71 | 386.49 |
| Oct 2026 | -6,574 | -1.8 | 31.95 | 13.71 | 380.75 |
| Oct 2026 | -7,488 | -1.9 | 33.62 | 13.71 | 401.07 |
| Oct 2026 | -7,750 | -2.0 | 34.10 | 13.71 | 406.76 |
| Oct 2026 | -7,271 | -1.9 | 33.22 | 13.71 | 395.35 |
| Oct 2026 | -7,880 | -2.0 | 34.34 | 13.71 | 407.77 |
ARS Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 33,658,000.0 | 22,681,000.0 | 28,087,000.0 | 32,501,000.0 |
| Net Profit | -62,339,000.0 | -60,618,000.0 | -41,324,000.0 | -51,151,000.0 |
| EPS | -0.6 | -0.6 | — | -0.5 |
ARS Pharmaceuticals, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 84,278,000.0 | 89,149,000.0 | 30,000.0 | 1,316,000.0 | — |
| Net Profit | -171,298,000.0 | 7,998,000.0 | -54,365,000.0 | -34,682,000.0 | — |
| EPS | -1.7 | 0.1 | -0.6 | -0.9 | — |
ARS Pharmaceuticals, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 327,652,000.0 | 351,153,000.0 | 233,188,000.0 | 281,435,000.0 | — |
| Total Liabilities | 213,394,000.0 | 94,355,000.0 | 2,428,000.0 | 8,549,000.0 | — |
| Total Equity | 114,258,000.0 | 256,798,000.0 | 230,760,000.0 | 272,886,000.0 | — |
Owes vs Owns
ARS Pharmaceuticals, Inc. owed $0.95 for every $1 it owned in Jun 2026, up from $0.03 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.95× | 0.65× | 0.27× | 0.01× | 0.03× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
ARS Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 74.8%Receivables 7.7%Inventory 2.6%Fixed assets (tangible) 0.8%Intangible assets 4.4%Other assets 9.8%
How it's funded — Dec 2025
Long-term debt 29.4%Payables 1.7%Other liabilities 34.0%Shareholders' equity 34.9%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 245.0 | 314.0 | 228.4 | 274.4 |
| Receivables | 25.3 | 8.2 | 0.7 | 1.0 |
| Inventory | 8.4 | 5.2 | 0.0 | 0.0 |
| Fixed assets (tangible) | 2.5 | 1.1 | 0.8 | 0.8 |
| Intangible assets | 14.5 | 7.4 | 0.6 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 32.0 | 15.3 | 2.7 | 5.3 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.2 | 0.2 |
| Long-term debt | 96.4 | 0.0 | 0.0 | 0.3 |
| Payables | 5.7 | 9.9 | 0.8 | 1.7 |
| Other liabilities | 111.3 | 84.4 | 1.4 | 6.4 |
| Shareholders' equity | 114.3 | 256.8 | 230.8 | 272.9 |
| Net tangible assets | 99.8 | 249.4 | 230.1 | 272.9 |
ARS Pharmaceuticals, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -170,866,000.0 | 13,548,000.0 | -59,266,000.0 | -40,078,000.0 | — |
| Investing Activities | 56,768,000.0 | -106,101,000.0 | -87,180,000.0 | -199,000.0 | — |
| Financing Activities | 104,598,000.0 | 72,399,000.0 | 6,899,000.0 | 190,732,000.0 | — |